What liver research gap did this study address?
Primary sclerosing cholangitis (PSC) is a rare, long-term liver disease in which inflammation and scarring slowly narrow the bile ducts. Its course differs greatly between people: some remain stable for years, while others progress to cirrhosis, need a liver transplant, or develop cholangiocarcinoma (CCA). Cancer is the leading cause of death in PSC, and CCA develops in about 7-20% of people with PSC over their lifetime. CCA is often found late, because current tools (the blood marker CA19-9 and imaging) struggle to tell cancer apart from PSC-related inflammation and scarring. Around 70% of people with PSC also live with inflammatory bowel disease (IBD).
Existing tools cannot yet reliably predict how an individual’s PSC will progress, partly because the biology driving progression is poorly understood. Earlier studies usually examined one type of molecule at a time.
What were the aims of this PSC study?
We wanted to find out whether molecules circulating in the blood carry a “fingerprint” of what is happening in PSC. They looked for blood patterns linked to:
- how severe PSC is, measured by routine liver blood tests (alkaline phosphatase and bilirubin) and by the degree of liver scarring (fibrosis);
- whether the person also has IBD;
- whether the person has developed cholangiocarcinoma (CCA).
The goal was to understand the biology behind PSC progression and identify possible blood markers for assessing cancer risk and monitoring the disease.
How was the research conducted?
Our team studied blood plasma from 33 people with PSC at Karolinska University Hospital in Stockholm, Sweden (followed up for two years), chosen to include people with and without IBD, milder and more advanced disease, and six people who had developed CCA.
From each sample, three types of molecules were measured at the same time (an approach known as “multi-omics”):
- 737 proteins: the working machinery of the body’s cells
- 1,083 metabolites: small molecules produced as the body processes food, bile, medicines and energy
- 4,573 microRNAs (miRNAs): tiny molecules that turn genes up or down
The team analysed this large dataset with two computer approaches: machine learning, which finds combinations of molecules that best separate groups of patients, and network analysis, which finds molecules that rise and fall together. They focused on molecules picked out by both methods and examined which biological processes these point to.
What were the main findings of the study?
The blood reflected the clinical picture
Blood profiles differed by disease severity and cancer status, and the three types of molecules told a consistent story.
More severe PSC had its own signature
51 molecules were linked to more severe disease by both methods. These included immune and bile-duct-lining proteins, bile acid-related molecules and miRNAs involved in scarring and inflammation, while molecules that protect cells from damage (glutathione-related) were lower.
Some features of severe PSC overlapped with those seen in bile duct cancer
Several of the miRNAs and proteins linked to severe PSC are known to be involved in cancer-related processes. This does not mean that people with more severe PSC have, or will develop, cancer.
IBD-related differences were subtle
They were detected only with machine learning and involved immune proteins and metabolites produced by gut bacteria, supporting a link between the gut and the liver in PSC.
Bile duct cancer had a distinct signature
56 molecules differed in people with CCA, including miRNAs known in bile duct cancer and proteins involved in inflammation and tissue structure, some newly linked to CCA. Substances that the liver normally processes, including breakdown products of caffeine, was lower, suggesting the liver’s ability to clear substances was reduced. The study did not examine whether coffee or diet play any role.
An “infection-like” pattern
In both severe PSC and CCA, the biological processes highlighted resembled the body’s response to infection, alongside cancer-related processes. This describes the pattern of the immune response; it does not show that PSC is caused by an infection.
Why are these research results important for PSC?
To our knowledge, this is the first study to combine circulating miRNAs, proteins and metabolites from the same people with PSC and PSC-related bile duct cancer.
The overlap between severe PSC and CCA supports the idea that cancer in PSC may develop gradually, through a strengthening of inflammatory, scarring and metabolic processes already active in advanced disease, rather than through a sudden change. The study also provides a shortlist of candidate blood markers that could be combined into future tests for monitoring PSC and assessing cancer risk.
This was a small, exploratory study at a single centre, with only six people with CCA. The results are therefore hypothesis-generating and must be confirmed in larger, independent groups of people with PSC before their usefulness can be judged.
What does this mean for people with PSC?
This research is a step towards understanding why PSC behaves so differently in different people.
If these findings are confirmed in larger studies, blood markers like these could help doctors identify people at higher risk of complications such as bile duct cancer, allowing monitoring to be tailored to each person, and may point towards new treatment targets.
Many thanks to Dr Ghada Nouairia for this summary.